

References



Ahmed SA, Al-joud, Fs, zaidah AW, Roshan TM, Rapiaah M, Abdullah m, Rasline H (2006). the prevalence of human cytomegalovirus Seropositivity among blood donors at the unit of blood transfusion Medicine, Hospital University sa in Malaysia. Southeast Asian J Trop Med Public Health 2006 Mar; 37 (2) 294-6.


Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003;3:1211-1215.

Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993 Apr; 55(4):752-756.

Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 (5): 1205-13

Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus

disease in solid organ transplant recipients. *Am J Transplant* 2007; 7 (9): 2106-13



Bao L, Dunham K, Stamer M, et al. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 2008; 14 (10): 1156-62

Bataille,V. Moal, J. Gaudart, M. Indreies, R. Purgus, B. Dussol ,C. Zandotti, Y. Berland, H.Vacher-Coponat. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression *Transpl Infect Dis* 2010; 12: 480-488.


BattiwallaM, Paplham P, Almyroudin NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. *Transpl Infect Dis* 2007; 9 (1): 28-32

Becker BN, Becker YT, Levenson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. *Am J Kidney Dis* 2002; 39: 1088–1095.

Bennett W. Immunosuppression with mycophenolic acid: one size does not fit all. *J Am Soc Nephrol* 2003; 14:2414-2418.

- Bernstein DI, Schleiss MR, Berencsi K, et al.** Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. *J Infect Dis* 2002; 185: 686.
- Bissinger, A.L., Singzer,C., Kaiserling, E., & Jahn, G. (2009).** Human cytomegalovirus as a direct pathogen correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. *J Med Virol* 67, 200-206.
- Bodziak K, Hricik D.** Minimizing the side effects of immunosuppression in kidney transplant recipients. *Transplantation* 2003; 8:160-165.
- Boeckh M, Nichols WG.** Immunosuppressive effects of betaherpesviruses. *Herpes* 2003; 10: 12.
- Boivin G, Goyette N, Gilbert C, et al.** Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. *J Med Virol* 2005; 77 (3): 425-9
- Bowen, E. F., Sabin, C. A., Wilson, P., Griffiths, P. D., Davery, C. C., Johnson, M. A., & Emery, V. C.(2006).** Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV- positive patients at high risk of CMV disease. *AIDS* 11, 889-893
-

- Brennan DC.** Cytomegalovirus in renal transplantation. *J Am Soc Nephrol* 2001; 12: 848–855.
- Brennan DC.** Faith supported by reason: mechanistic support for the use of polyclonal antibodies in transplantation. *Transplantation* 2003;75:577-582.
- Briganti E, Russ G, McNeil J, Atkins R, Chadban S.** Risk of renal allograft loss from recurrent glomerulonephritis. *N Engl J Med* 2002;347:103-109.
- Buonuomo, PS, Maurizi, P, Valentini, P, et al.** Successful treatment with oral valganciclovir in immunocompetent infant with gastrointestinal manifestations of cytomegalovirus infection. *J Perinatol* 2006; 26:648.
- Burdmann EA; Andoh TF; Yu L; Bennett WM.** Cyclosporine nephrotoxicity. *Semin Nephrol* 2003 Sep;23(5):465-76.
- Burton, G. J., & Watson, A.L. (2000).** the structure of the human placenta: implicatios for initiating and defending against virus infection. *Rev Med Virol* 7, 219-228.
- Butler JA, Peveler RC, Roderick P, Smith PW, Home R, Mason JC.** Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. *Nephrol Dial Transplant.* 2004 Dec; 19(12):3144-3149.



- Carpenter, CB.** Immunosuppression in organ transplantation. *N Engl J Med* 1990; 322:1224.
- Cecka JM.** Results of more than 1000 recent living-unrelated donor transplants in the United States. *Transplant Proc* 1999; 31: 234.
- Cecka JM.** The UNOS transplant registry. In Cecka JM, Terasaki PI, eds. *Clinical Transplants 2002*. Los Angeles: UCLA, 2002: 1-18.
- Cervera C, Lozano F, Saval N, et al.** The influence of innate immunity gene receptors polymorphisms in renal transplant infections. *Transplantation* 2007; 83 (11): 1493-500
- Chemaly RF, Yen-Lieberman B, Castilla EA, et al.** Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. *J Clin Microbiol* 2004; 42: 2168.
- Cohen, JI, Corey, GR.** Cytomegalovirus infection in the normal host. *Medicine (Baltimore)* 1985; 64:100.
- Cole EH, Johnston O, Rose CL, Gill JS.** Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. *Clin J Am Soc Nephrol*. 2008 May; 3(3):814-21.
- Cordonnier C, Escrudier E, Nicholas J-C, Fleury J, Deforfes L, Ingrand D, Bricout F, Bernaudin J-F. (2007).** Evaluation of


three assays on alveolar lavage fluid in the diagnosis of cytomegalovirus pneumonitis after bone marrow transplantation. *J infect Dis*;159:495-500

Cosio FG, Pelletier RP , Falkenhain ME, et al. Impact of acute rejection and early allograft function on renal allograft survival. *Transplantation* 1997; 63: 1611-15.

Costa C, Touscoz GA, Bergallo M, Terlizzi ME, Astegiano S, Sidoti F, Sinesi F, Segoloni GP, Cavallo R. Non-organ-specific and anti-endothelial antibodies in relation to CMV infection and acute rejection in renal transplant recipients. *Clin Transplant* 2009 DOI: 10.1111/j.1399-0012.

Courcelle, C. T., Courcelle, J., Prichard, M. N., & Mocarski, E. S. (2009). Requirement for uracil- DNA glucosylase during the transition to late phase cytomegalovirus DNA replication. *J Virol* 75, 7592-7601.

Couzi L, Levaillant Y, Jamaï A, et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. *J Am Soc Nephrol* 2010 Jan; 21 (1): 181-8



Danovitch GM, Cecka JM. Allocation of deceased donor kidneys: past, present, and future. *Am J Kidney Dis* 2003; 42: 882-90.

De Fijter JW. The impact of age on rejection in kidney transplantation.

Drugs Aging. 2005; 22(5):433-49.


De Silva, SR, Chohan, G, Jones, D, Hu, M. Cytomegalovirus papillitis in an immunocompetent patient. J Neuroophthalmol 2008; 28:126.

Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82 (1): 30-5

Dittrich E; Schmaldienst S; Soleiman A; Horl WH; Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004 May; 17(4) 72, 1014

Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81 (8): 1106-11

Drew WL, Miner RC, Marousek GI, et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37 (2): 124-7



Eddleston, M, Peacock, S, Juniper, M, Warrell, DA. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 1997; 24:52.

Efferth T, Romero MR, Wolf DG, et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008; 47 (6): 804-11

Eid AJ, Arthurs SK, Deziel PJ, et al e. Emergence of drugresistant cytomegalovirus in the ra of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22 (2): 162-70

Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010 Jan; 10 (1): 157-61

Eid AJ, Bakri SJ, Kijpittayarit S, et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008 Feb; 10 (1): 13-

Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97: 8039.

Emery, V.C. (2008): Investigation of CMV disease in immunocompromised patients . Clin . Patho 1 .; 54 : 84-8 .



Fellstrom B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H; ALERT Study Group. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal

transplantation. Am J Transplant. 2005 Aug; 5(8):1986-91.

Fernandez-Ruiz, M, Mufioz-Codoceo, C, Lopez-Medrano, F, et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med 2008; 47:1963.

Fernando AB Colugnati, Stephanie AS Staras, Sheila C Dollard and Michael J Cannon. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infectious Diseases 2007, 7:71.

Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007; 9 (3): 203-10

Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007; 9 (3): 203-10

Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007; 21: 149.

Fridlender, ZG, Khamaisi, M, Leitersdorf, E. Association between cytomegalovirus infection and venous thromboembolism. Am J Med Sci 2007; 334:111.



Gabreil MD anovitch. Handbook of kidney transplantation,4th edition2004;279-333.

Gandhi, M.K., Khanna, R. (2004). Human cytomegalovirus: clinical aspects,immune regulation, and emering treatments .Lancet Infect. Dis. 4, 725-738.

Gerna, G., Percivalle, E., Baldanti, F., Sozzani, s., Lanzarini, p., Genini, E., Lilleri, D., & Revello, M. G. (2005b). Human cytomegalvirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74, 5629-5638.

Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49: 873.

Gill JS, Tonelli M, Mix CH. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int. Feb 2004; 65(2):692-9.

Gillespie, GM, Wills, MR, Appay, V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74:8140.


Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.

Transplantation 2003; 76:798-803.

Griffiths, P. D. (2002). Cytomegalovirus. In A. J. Zuckerman, J. E. Banatvala, & J.R. Pattison (Eds.), *Principles and Practice of Clinical Virology* (pp. 79-116). London: John Wiley and Sons.

Griffiths, P.D., Walter, S. (2005). *Curr. Opin. Infect. Dis.* 18, 241-245.

Gyulai, Z., Endresz, V., Burian, K., Pimcus, S., Toldy, J., Cox, W. I., Meric, C., Plotkin, S., Gnczol, E., & berecsi, K. (2008) Cytotoxic t lymphocytes (ctl) responses to human cytomegalovirus pp65, IEI-Exon 4, gB, pp150 and pp28 in healthy individuals: reevaluation of prevalence of IEI-specific CTLs. *J Infect Dis* 181, 1537-1546.



Halloran PF, Hunsicker LG. Delayed graft function. *Am J Transplant* 2001; 1: 115-20.

Hamprecht K, Eckle T, Prix L, et al. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: Pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. *Infect Dis* 2003; 187: 139.

Hariharan S, Johnson C, Bresnahan B, Taranto S, McIntosh M, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. *N Engl J Med* 2000; 342: 605-612.

- Helanterä I, Koskinen P, Finne P, et al.** Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. *Transpl Int* 2006; 19 (11): 893-900
- Helderman JH, Bennett WM, Cibrik DM, Kaufman DB, Klein A, Takemoto SK.** Immunosuppression: practice and trends. *Am J Transplant.* 2003; 3 Suppl 4:41-52.
- Hill JA, Hummel M, Starling RC, et al.** A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. *Transplantation* 2007; 84 (11): 1436-42
- Ho, M. (2001).** Cytomegalovirus. In G.L. Mandell, J. E. Bennet, & R. Dolin (Eds.), *Principles and Practices of Infectious Diseases* (pp.1351-1364). New York: Churchill Livingstone.
- Hodson EM, Jones CA, Webster AC, et al.** Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. *Lancet* 2007; 365 (9477): 2105-15
- Horvat LD, Shariff SZ, Garg AX.** Global trends in the rates of living kidney donation. *Kidney Int.* 2009 May; 75(10):1088-98.
- Hostetler KY.** Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. *Antiviral Res* 2009 May; 82 (2): A84-98
- Humar A, Kumar D, Boivin G, et al.** Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ
-

transplant patients with CMV disease. J Infect Dis 2002; 186 (6): 829-33

Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5 (6): 1462-8


Humar A, Lebranchu Y, Vincenti F, et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients. American Journal of Transplantation 2010; 10: 1228-1237.

Humar A, Siegal D, Moussa G, et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005; 192 (7): 1154-7

Humar A, Snyderman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl. 4:

Humar, A, Payne, WD, Sutherland, DE, Matas, AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69:235.


Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26 (3): 753-5



Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR, Matas AJ. Long-term consequences of kidney donation. *N Engl J Med.* 2009 Jan 29; 360(5):522-3.



Johnston A; He X; Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. *Transplantation.* 2006 Dec 15; 82(11):1413-8.



Kahan B, Camardo J. Rapamycin: clinical results and future opportunities. *Transplantation* 2001;72:1181-1193.

Kahan, B. D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. *Lancet* 2000; 356, 194-202.

Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. *Ann Intern Med* 2005; 143 (12): 870-80

Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR. The evaluation of renal transplantation candidates: clinical practice guidelines. *Am J Transplant*. 2001; 1: 23-95.

Keown P. Improving quality of life. The new target for transplantation. *Transplantation* 2001; 72 (Suppl 12): S67-74.

Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. *Am J Transplant* 2006; 6 (9): 2134-43

Kim SJ, Schaubel DE, Jeffery JR, Fenton SS. Centre-specific variation in renal transplant outcomes in Canada. *Nephrol Dial Transplant*. 2004 Jul; 19(7):1856-61.

Kirk AD, Hale DA, Mannon RB and Kleiner DE: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Alemtuzumab (Campath 1H). *Transplantation* 2003; (7691): 120-129.

Kletzmayer J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on CMV disease in CMV high-risk renal transplant recipients. *J Am Soc Nephrol* 1996; 7: 325–330.

Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. *Am J Transplant* 2008; 8:

975.

Kotton, CN, Kumar, D, Caliendo, AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. *Transplantation* 2010; 89:779-795.

Kuhl, U, Pauschinger, M, Noutsias, M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. *Circulation* 2005; 111:887.

Kyto, V, Vuorinen, T, Saukko, P, et al. Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. *Clin Infect Dis* 2005; 40:683.



Land W. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. *Transplantation* 2005; 79: 505-14.

Lazzarotto, T., Spezzacatena, P., Varani, S., Gabrielli, L., Pradelli, P., Guerra, B., & Landini, M. P. (2009). Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. *Clin Diagn Lab Immunol* 6, 127-129

Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically 980 Eid &

Razonable 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (8)

Limaye AP, Bakthavatsalam R, Kim HW et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2008; 78: 1390-1396.

Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17 (4): 265-73


Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388.

Loeffler J, SteffensM, Arlt EM, et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 2006; 44 (5): 1847-50

Lowance D, Neumayer H, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462–1470.

Lucas KG. Vaccine therapy in treating patients who have undergone a donor stem cell transplant and have cytomegalovirus infection that has not responded to therapy [ClinicalTrials.gov identifier

NCT00509691]. US National Institutes of Health, ClinicalTrials.gov [online]. from URL: <http://www.clinicaltrials.gov> [Accessed 2010 Mar 23]



Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta 1 expression and promotes tumor progression. *Transplantation* 2003; 76:597-602.

Margreiter R, Klempnauer J, Neuhausc et al. Alemtuzumab (Campath-IH) and Tacrolimus Monotherapy after Renal Transplantation: Results of a Prospective Randomized Trial. *American Journal of Transplantation* 2008; 8: 1480-1485.

Marks WH, Wagner D, Pearson TC, et al. Organ donation and utilization, 1995-2004: entering the collaborative era. *Am J Transplantation* 2006; 6: 1101-1110.

Matas AJ, Gillingham KJ, Humor A et al.; Immunologic and non-immunologic factors: different risks for cadaver and living donor transplantation. *Transplantation* 2000; 69:54.

Matas AJ, Lawson W, McHugh L, et al. Employment patterns after successful kidney transplantation. *Transplantation* 1996; 61: 729-33

Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant

recipients after preemptive therapy with valganciclovir. J Infect Dis 2005 ; 191 (1): 89-92

Meier-Kriesche, HU, Schold, JD, Srinivas, TR, Kaplan, B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378.

Mettenleiter, T. C. (2008). herpesvirus assembly and egress. J Virol 76, 1537-1547.

Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75(5):657-662.


Midtvedt K; Hjelmessaeth J; Hartmann A; Lund K; Paulsen D; Egeland T; Jenssen T. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004 Dec; 15(12):3233-9.

Miller L. Cardiovascular toxicities of immunosuppressive agents. Transplantation 2002; 2:807-902.

Mocarski, E. S., & Courcelle, C. T. (2009). Cytomegalovirus and their replication. In D. Knipe, & P.Howley (Eds.), Fields Virology (pp. 2629-2673). Philadelphia: Lippincott, Williams and Wilkins

Molina MG, Seron D, del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish


Cooperative Study Group of Chronic Allograft Nephropathy.
Transplantation 2004; 77:215



Nebbia G, Mattes FM, Cholongitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13 (1): 130-5

Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867.

Norman DJ, Kahanal, Stuart Jr, FP et al.: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993, 55: 44-50.




Ohkuchi A , Minukami H , Suzuki (2001) : liver dysfunction in late pregnancy : CMV-induced hepatitis or the HELLP syndrome . J Obstet Gynaecol Res . Dec ; 27 (6) : 319-23

Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-72.

Opelz G; Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet* 2005; 365: 1570-6.

Opelz G; Dohler B. Cyclosporine and long-term kidney graft survival. *Transplantation* 2001 Oct 15;72(7): 1267-73.

Ozdemir FN, Akgul A, Altunoglu A, et al. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. *Transplant Proc* 2007; 39 (4): 990-2



Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. *N Engl J Med* 2009; 360: 1191.

Pass, R. F. (2005). Cytomegalovirus. In D. Knipe, & P. Howley(Eds), *Field Virology* (pp. 2675-2705). Philadelphia : Lippincott, Williams and Wilkins.

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant.* 2004;4(4):611-20.


Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. *J Infect Dis* 2002; 185 (7): 854-6

- Penfold, M. E., Dairaghi, D.J., Duke, G. M., Saedurup, N., Mocarski, E. S., Kemble, G.W., & Schall, T. j. (1999).** Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci USA 96, 9839-9844
- Phillips, C. A., Fanning, W.L., & Gump, D.W. (1977).** Cytomegalovirus in immunologically normal adult . JAMA 238, 2299-2300.
- Plachter, B., Sinzger, C., & Jahn, G. (1996).**Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 46, 195-261.
- Plotkin SA, Smiley ML, Friedman HM, et al.** Townevaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984; 1 (8376): 528-3
- Pollard,A.B.(2002).** cytomegalovirus infection in renal,heart,heart-lung &liver transplantation. Peadiatr Infect Dis J 7, 97-102.
- Ponticelli C, Villa M, Cesana B, et al.** Risk factors for late kidney allograft failure. Kidney Int 2002; 62: 1848-52.
- Ponticelli C; Minetti L; Di Palo FQ; Vegeto A; Belli L; Corbetta G; Tarantino A; Civati G.** The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 1988 May; 45(5):908-13.
- Port FK, Merino RM, Goodrich NP, Wolfe RA.** Recent trends and results for organ donation and transplantation in the United States, 2005. Is J Transplant 2006; 6: 1095-100.
-

Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. *AmJ Transplant* 2009; 5: 218-227.

Prommool S, Jhangri GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. *J Am Soc Nephrol*. 2000 Mar; 11(3):565-73.

Quiroga I, McShane P, Koo DD, Gray D, Friend PJ, Fuggle S, Darby C. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. *Nephrol Dial Transplant*. 2006 Jun;21(6): 2003; 2: 203-206.



Raymund R , Kelly B , Hester VC (2002) : the pathogenesis of hepatitis C virus is influenced by cytomegalovirus . *Clin Infect. Dis.*; 35,947-981

Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. *Transplantation* 2002; 73: 968.

Razonable RR, Paya CV. Herpes virus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. *Herpes* 2003; 10 (3): 60-5

- Razonable RR, Rivero A, Brown RA, et al.** Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. *Clin Transplant* 2003; 17 (2): 114-2
- Razonable RR.** Immune-based therapies for cytomegalovirus infection. *Immunotherapy* 2010; 2 (1): 117-30
- Razonable, RR, Limaye, RR.** Cytomegalovirus infection after solid organ transplantation. In: *Transplant Infections*, 3rd ed, Bowden, RA, Ljungman, P, Snyderman, DR (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.328.
- Reischig T, Jindra P, Hes O, et al.** Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. *Am J Transplant* 2008; 8: 69.
- Rene, E., Marche, C., Chevalier, T., Rouzioux, C., Regnier, B., Saimot, A. G., Nsege, Y., Matheron, S., Leport, C., & Wolff, B. (2001).** Cytomegalovirus Colitis in Patients with acquired immunodeficiency syndrome. *Dig Dis Sci* 33, 741-750
- Revello, M. G., Lilleri, D., Zavattoni, M., Stronati, M., Bollani, L., Middeldorp, J. M., & Gerna, G. (2001).** Human cytomegalovirus immediate-early messenger RNA in blood of pregnant woman with primary infection and of congenitally infected newborns. *J Infect Dis* 184, 1078-1081
- Revollo, M. G., Zavattoni, M., Furione, M., Baldanti, F., & Gerna, G.(1999).**Quantification of human cytomegalovirus DNA in
-

amniotic fluid of mothers of congenitally infected fetus. J Clin Microbiol 37, 3350-3352

Rhen T; Cidlowski JA. Anti-inflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 2005 Oct 20; 353(16):1711-23.

Ross, SA, Arora, N, Novak, Z, et al. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010; 201:386.

Ryan KJ, Ray CG. (2004). Sherris Medical Microbiology (4th ed.). McGrawHill. pp. 556; 566-9.



Salvadori M, Rosati A, Bock A, Chapman J, Dussol B, Fritsche L, Kliem V, Lebranchu Y, Oppenheimer F, Pohanka E, Tufveson G, Bertoni E. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation. 2006 Jan 27; 81(2):202-6.

San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 (7): 875-82

San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of

cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 (7): 875-82

Schnitzler Ma, Lowell Ja, Hmiel Sp, et al: Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation The importance of HLA-DR matching. J Am Soc Nephrol.2003. 14:780-785.

Schroeder R, Michelon T, Fagundes I, et al. Antigenemia for cytomegalovirus in renal transplantation: Choosing a cutoff for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 2005; 37: 2781.

Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Clin Microbiol 1999; 37: 2291.

Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46 (9): 1455-7

Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46 (9): 1455-7

Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC;

- Henning AK; Holman J Jr; First MR.** Conversion From Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-Month Results of the CRAF Study. *Transplantation* 2008 May 15; 85(9):1261-1269.
- Siegal, DS, Hamid, N, Cunha, BA.** Cytomegalovirus colitis mimicking ischemic colitis in an immunocompetent host. *Heart Lung* 2005; 34:291.
- Sinzger, C., Plachter, B., Grefte, A., The, T. H., &Jahn, G. (2006).** tissue macrophages are infected by human cytomegalovirus. *J Infect Dis* 173, 240-245.
- Slavin S.** Adoptive immunotherapy for CMV disease [ClinicalTrials.gov identifier NCT00159055]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: <http://www.clinicaltrials.gov> [Accessed 2010 Mar 23]
- Small LN, Lau J, Snyderman DR.** Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. *Clin Infect Dis* 2006; 43 (7): 869-80
- Spital A.** Living kidney donors: still a valuable resource. *Curr Opin Organ Transplant* 1998; 3: 205-11.
- Squizzato, A, Ageno, W, Cattaneo, A, Brumana, N.** A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. *Clin Infect Dis* 2007; 44:13.

Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. *Am J Transplant.* 2007 Mar; 7(3):586-94.

Stagno, S., Pass, R. F., Dworsky, M. E., & Alford, C. A., Jr. (1992). Maternal cytomegalovirus infection and perinatal transmission. *Clin Obstet Gynecol* 25, 563-576.

Staras, SA, Dollard, SC, Radford, KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. *Clin Infect Dis* 2006; 43:1143.

Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. *Clin Microbiol Infect.* 2007;13(10):953-963.




Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. *Transplantation* 1998; 65: 1533-42.

Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. *Transplantation* 2005 Nov 15; 80(9):1194-7.

Thomas LD, Milstone AP, Miller GG, et al. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung

transplantation with a delayed ganciclovir regimen. Clin Transplant 2009; 23 (4): 476-83


Tullius SG, Reutzel-Selke A, Bachmann U, Jurisch A, Nieminen-Kelha M, Pratschke J, Jonas S, Steinmuller T, Volk HD, Neuhaus P. Influence of recipient and donor age on long-term renal allograft function in an experimental model. Transplant Proc. 2001 Nov-Dec;33(7-8):3345-6.



van Boxtel, LA, van der Lelij, A, van der Meer, J, Los, LI. Cytomegalovirus as a cause of anterior uveitis in immunocompetent patients. Ophthalmology 2007; 114:1358.

van Hest RM; Mathot RA; Pescovitz MD; Gordon R; Mamelok RD; van Gelder T. Explaining variability in mycophenolic Acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic Acid in renal transplant recipients. J Am Soc Nephrol. 2006 Mar; 17(3):871-80.

Vega O, Cardenas G, Correa-Rotter R, Albert J, Morales-Buenrostro LE. Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. Rev Invest Clin. 2008 Mar-Apr; 60(2):82-6.



Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. *Transplantation* 2007; 83 (7): 874-82

Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonist for renal transplant recipients: a meta-analysis of randomized trials. *Transplantation* 2004; 77:166-176.

Webster AC; Woodroffe RC; Taylor RS; Chapman JR; Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. *BMJ* 2005 Oct 8;331(7520):810.

Weclawiak H, Nassim Kamar, Catherine Mengelle, et al. Preemptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients. *Transplant International* 23 (2010) 1056-1064.

West P, Schmiedeskamp M, Neeley H, et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. *Transpl Infect Dis* 2008; 10: 129.

Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: A longitudinal study of lung transplant recipients. *J Infect Dis* 2004; 190: 1076.

Whiting JF, Golconda M, Smith R, et al. Economic cost of expanded
Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and
immunogenicity of a bivalent cytomegalovirus DNA vaccine in
healthy adult subjects. J Infect Dis 2008; 197: 1634.

Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for
prevention of cytomegalovirus infection in allogeneic stemcell
transplant recipients: a multicenter, randomized, double-blind,
placebo-controlled, dose-ranging study. Blood 2008; 111 (11):
5403-10

Woodward RS; Kutinova A; Schnitzler MA; Brennan DC. Renal graft
survival and calcineurin inhibitor. Transplantation 2005 Sep 15;
80(5):629-33



Zamora, MR. Cytomegalovirus and lung transplantation. Am J
Transplant 2004; 4:1219.